4220 related articles for article (PubMed ID: 26921134)
1. Alzheimer's disease.
Scheltens P; Blennow K; Breteler MM; de Strooper B; Frisoni GB; Salloway S; Van der Flier WM
Lancet; 2016 Jul; 388(10043):505-17. PubMed ID: 26921134
[TBL] [Abstract][Full Text] [Related]
2. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
[TBL] [Abstract][Full Text] [Related]
3. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
Fortea J; Vilaplana E; Carmona-Iragui M; Benejam B; Videla L; Barroeta I; Fernández S; Altuna M; Pegueroles J; Montal V; Valldeneu S; Giménez S; González-Ortiz S; Muñoz L; Estellés T; Illán-Gala I; Belbin O; Camacho V; Wilson LR; Annus T; Osorio RS; Videla S; Lehmann S; Holland AJ; Alcolea D; Clarimón J; Zaman SH; Blesa R; Lleó A
Lancet; 2020 Jun; 395(10242):1988-1997. PubMed ID: 32593336
[TBL] [Abstract][Full Text] [Related]
4. [Brain imaging of Alzheimer' disease: state of the art and perspectives for clinicians].
Trombella S; Assal F; Zekry D; Gold G; Giannakopoulos P; Garibotto V; Démonet JF; Frisoni GB
Rev Med Suisse; 2016 Apr; 12(515):795-8. PubMed ID: 27276723
[TBL] [Abstract][Full Text] [Related]
5. Preclinical sporadic Alzheimer's disease: target for personalized diagnosis and preventive intervention.
Vanitallie TB
Metabolism; 2013 Jan; 62 Suppl 1():S30-3. PubMed ID: 23021038
[TBL] [Abstract][Full Text] [Related]
6. Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.
Pascoal TA; Mathotaarachchi S; Shin M; Park AY; Mohades S; Benedet AL; Kang MS; Massarweh G; Soucy JP; Gauthier S; Rosa-Neto P;
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):1021-1030. PubMed ID: 29396637
[TBL] [Abstract][Full Text] [Related]
7. Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease.
Pascoal TA; Mathotaarachchi S; Mohades S; Benedet AL; Chung CO; Shin M; Wang S; Beaudry T; Kang MS; Soucy JP; Labbe A; Gauthier S; Rosa-Neto P
Mol Psychiatry; 2017 Feb; 22(2):306-311. PubMed ID: 27021814
[TBL] [Abstract][Full Text] [Related]
8. Molecular imaging of dementia.
Mori T; Maeda J; Shimada H; Higuchi M; Shinotoh H; Ueno S; Suhara T
Psychogeriatrics; 2012 Jun; 12(2):106-14. PubMed ID: 22712644
[TBL] [Abstract][Full Text] [Related]
9. EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease.
Gaubert S; Raimondo F; Houot M; Corsi MC; Naccache L; Diego Sitt J; Hermann B; Oudiette D; Gagliardi G; Habert MO; Dubois B; De Vico Fallani F; Bakardjian H; Epelbaum S;
Brain; 2019 Jul; 142(7):2096-2112. PubMed ID: 31211359
[TBL] [Abstract][Full Text] [Related]
10. [Development of Disease-modifying Therapy for Alzheimer's Disease].
Akiyama H
Brain Nerve; 2016 Apr; 68(4):463-72. PubMed ID: 27056864
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers, ketone bodies, and the prevention of Alzheimer's disease.
VanItallie TB
Metabolism; 2015 Mar; 64(3 Suppl 1):S51-7. PubMed ID: 25468143
[TBL] [Abstract][Full Text] [Related]
12. Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum.
Jones DT; Graff-Radford J; Lowe VJ; Wiste HJ; Gunter JL; Senjem ML; Botha H; Kantarci K; Boeve BF; Knopman DS; Petersen RC; Jack CR
Cortex; 2017 Dec; 97():143-159. PubMed ID: 29102243
[TBL] [Abstract][Full Text] [Related]
13. In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease.
Dronse J; Fliessbach K; Bischof GN; von Reutern B; Faber J; Hammes J; Kuhnert G; Neumaier B; Onur OA; Kukolja J; van Eimeren T; Jessen F; Fink GR; Klockgether T; Drzezga A
J Alzheimers Dis; 2017; 55(2):465-471. PubMed ID: 27802224
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective.
Shokouhi S; Campbell D; Brill AB; Gwirtsman HE;
Brain Pathol; 2016 Sep; 26(5):664-71. PubMed ID: 27327527
[TBL] [Abstract][Full Text] [Related]
15. Is amyloid-β harmful to the brain? Insights from human imaging studies.
Jagust W
Brain; 2016 Jan; 139(Pt 1):23-30. PubMed ID: 26614753
[TBL] [Abstract][Full Text] [Related]
16. Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary.
Rabinovici GD; Karlawish J; Knopman D; Snyder HM; Sperling R; Carrillo MC
Alzheimers Dement; 2016 Apr; 12(4):510-5. PubMed ID: 27103054
[TBL] [Abstract][Full Text] [Related]
17. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.
Jack CR; Wiste HJ; Weigand SD; Therneau TM; Knopman DS; Lowe V; Vemuri P; Mielke MM; Roberts RO; Machulda MM; Senjem ML; Gunter JL; Rocca WA; Petersen RC
Lancet Neurol; 2017 Jun; 16(6):435-444. PubMed ID: 28456479
[TBL] [Abstract][Full Text] [Related]
18. Amyloid and Tau Biomarkers in Subjective Cognitive Impairment.
Colijn MA; Grossberg GT
J Alzheimers Dis; 2015; 47(1):1-8. PubMed ID: 26402749
[TBL] [Abstract][Full Text] [Related]
19. Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials.
Ossenkoppele R; van der Kant R; Hansson O
Lancet Neurol; 2022 Aug; 21(8):726-734. PubMed ID: 35643092
[TBL] [Abstract][Full Text] [Related]
20. Low amyloid-β deposition correlates with high education in cognitively normal older adults: a pilot study.
Yasuno F; Kazui H; Morita N; Kajimoto K; Ihara M; Taguchi A; Yamamoto A; Matsuoka K; Kosaka J; Kudo T; Iida H; Kishimoto T
Int J Geriatr Psychiatry; 2015 Sep; 30(9):919-26. PubMed ID: 25425062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
